Novartis' Lotrel 5/40 mg and 10/40 mg dosage strengths approved

By Elaine Rigoli

Tampa, Fla., June 9 - Novartis Pharmaceuticals Corp. has received marketing approval from the Food and Drug Administration for Lotrel (amlodipine besylate/benazepril HCl) 5/40 mg and 10/40 mg.

The new dosing strengths combine the calcium channel blocker (CCB) amlodipine with the highest available dose of the ACE inhibitor benazepril, according to a news release.

Lotrel has the broadest marketed dosing range of any CCB and ACE inhibitor combination, the release said.

The additional 5/40 mg and 10/40 mg doses of Lotrel will be available this month, after which Lotrel will be marketed in six dosage strengths - 2.5/10 mg, 5/10 mg, 5/20 mg, 10/20 mg, 5/40 mg and 10/40 mg.

Novartis, located in East Hanover, N.J., is an affiliate of Basel, Switzerland-based Novartis AG.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.